Abstract
The expanding field of monoclonal antibody-based pharmaceuticals has triggered increased interest in analytical characterization of these large proteins and in understanding of their heterogeneity and degradation pathways. As a result, a large number of enzymatic modifications as well as chemical and physical degradations have been reported in monoclonal antibodies in recent years. Most heterogeneity is related to changes in the surface charge of the antibody, either directly, as a change in the number of charged residues, or indirectly as a chemical or physical alteration that changes surface-charge distribution. This review presents an overview of the sources of charge-related heterogeneity in monoclonal antibodies and the methods used for their detection. A detailed section is dedicated to deamidation of asparagine and isomerization of aspartic acid residues, two ubiquitous degradation pathways detected in antibodies and other proteins as well. Finally, kinetic modeling of the accumulation of antibody variants is presented as a tool to determine the expected fraction of molecules that have undergone one or more degradation reactions.
Keywords: Monoclonal antibody, charge heterogeneity, degradation, chromatography, deamidation, isomerization
Current Pharmaceutical Biotechnology
Title: Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods
Volume: 9 Issue: 6
Author(s): J. Vlasak and R. Ionescu
Affiliation:
Keywords: Monoclonal antibody, charge heterogeneity, degradation, chromatography, deamidation, isomerization
Abstract: The expanding field of monoclonal antibody-based pharmaceuticals has triggered increased interest in analytical characterization of these large proteins and in understanding of their heterogeneity and degradation pathways. As a result, a large number of enzymatic modifications as well as chemical and physical degradations have been reported in monoclonal antibodies in recent years. Most heterogeneity is related to changes in the surface charge of the antibody, either directly, as a change in the number of charged residues, or indirectly as a chemical or physical alteration that changes surface-charge distribution. This review presents an overview of the sources of charge-related heterogeneity in monoclonal antibodies and the methods used for their detection. A detailed section is dedicated to deamidation of asparagine and isomerization of aspartic acid residues, two ubiquitous degradation pathways detected in antibodies and other proteins as well. Finally, kinetic modeling of the accumulation of antibody variants is presented as a tool to determine the expected fraction of molecules that have undergone one or more degradation reactions.
Export Options
About this article
Cite this article as:
Vlasak J. and Ionescu R., Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods, Current Pharmaceutical Biotechnology 2008; 9 (6) . https://dx.doi.org/10.2174/138920108786786402
DOI https://dx.doi.org/10.2174/138920108786786402 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention
Current Cancer Drug Targets Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Current Medicinal Chemistry Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer
Current Drug Delivery Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Combination Therapy with Arsenic Trioxide for Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Isolation of a New Trypsin Inhibitor from the Faba Bean (Vicia faba cv. Giza 843) with Potential Medicinal Applications
Protein & Peptide Letters